Company Overview
Well-established medical device company specializing in non-invasive electro-therapy solutions designed to alleviate pain and improve patient outcomes. The company has built a strong reputation over more than two decades by providing high-quality Transcutaneous Electrical Nerve Stimulation (TENS) devices and related therapeutic products to healthcare providers and their patients.
Core Competencies
Differentiators
Product and Payer Mix
The Company’s product mix is 90% Electrodes, 5% TENS Devices, and 5% Braces.
The Company’s payer mix consists of 100% Commercial Insurance.
Staff Overview
The Company’s team is expected to remain in place under new ownership, including 8 employees and 7 independent contractors.
Financial Overview
The Company’s revenue has increased significantly from 2022 to 2025 at a compounded annual growth rate (CAGR) of 84% while achieving a 34% adjusted EBITDA margin.
The Company expects to continue its double-digit growth rates from a strong first quarter of new patients in 2026. Total 2026 revenues are forecasted to grow to $2.9 million and $1.
1 million in Adjusted EBITDA (38%).
Asking Price
The asking price is $9 Million plus an earn-out going forward. The Seller will consider a majority sale and rollover of equity while remaining involved post-close.
This does not include cash, receivables, or working capital.